Indications of Ruxolitinib

1. Myelofibrosis

Ruxolitinib is indicated for the treatment of intermediate- or high-risk myelofibrosis in adults, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.

2. Polycythemia Vera

Ruxolitinib is indicated for the treatment of polycythemia vera in adults with an inadequate response to or intolerance of hydroxyurea.

3. Acute Graft-Versus-Host Disease

Ruxolitinib is indicated for the treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients aged 12 years and older.

4. Chronic Graft-Versus-Host Disease

Ruxolitinib is indicated for the treatment of chronic graft-versus-host disease in adult and pediatric patients aged 12 years and older after failure of one or two lines of systemic therapy.